Cyclosporin for treatment of subcutaneous panniculitis-like T-cell lymphoma: report of one case and review of literature
10.3760/cma.j.issn.1009-9921.2018.08.007
- VernacularTitle: 环孢素治疗皮下脂膜炎样T细胞淋巴瘤一例并文献复习
- Author:
Yuan HUANG
1
;
Zhenling LI
1
;
Hongyan LIU
2
Author Information
1. Department of Hematology, China-Japan Friendship Hospital, Beijing 100029, China
2. Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China
- Publication Type:Journal Article
- Keywords:
Subcutaneous panniculitis-like T-cell lymphoma;
Cyclosporin;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2018;27(8):479-482
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of cyclosporin (CsA) on initial, relapsed or refractory subcutaneous panniculitis-like T-cell lymphoma (SPTCL).
Methods:The clinical data of one case with long-survival SPTCL in China-Japan Friendship Hospital was retrospectively analyzed, and the literature was reviewed.
Results:After CsA treatment as the initial therapy, the patient obtained rapid response and complete remission (CR). Lymphoma occurred relapse several times, but the use of CsA could got rapid remission. CR sustained from 1 to 6 years after drug withdrawal. However, CsA did not bring remission after the recent relapse. Then CHOP-like regimen was carried out, and partial remission could be reached. The patient achieved CR and 22 years survival time with CsA maintenance therapy until now.
Conclusion:CsA has a favorable effect on initial, relapsed or refractory SPTCL.
